Please use this identifier to cite or link to this item:
Title: Advances in multimodal treatment for stage IIIA-N2 non-small cell lung cancer
Servicio de Oncología. Hospital Universitario de Fuenlabrada
Servicio de Oncología Radioterápica Hospital Universitario de Fuenlabrada
Servicio de Neumología. Hospital Universitario de Fuenlabrada
Servicio de Medicina Nuclear. Hospital Universitario de Fuenlabrada
Mesh: Carcinoma, Non-Small-Cell Lung
Combined Modality Therapy
Decs: Terapia Combinada
Carcinoma de Pulmón de Células no Pequeñas
Issue Date: 22-Apr-2021
Citation: J Clin Transl Res.2021 Apr;(7)2:185-198
Abstract: In Stage IIIA-N2 non-small cell lung cancer (NSCLC), the accuracy of combined positron-emission tomography/computed tomography imaging (PET-CT), together with mediastinal staging techniques, has led to a wide range of challenging clinical scenarios in terms of therapeutic management. Concurrent chemoradiotherapy followed by consolidation immunotherapy remains the standard of care. In patients with potentially-resectable disease, surgery plays an important role in multimodal therapy. The introduction of targeted therapies and immune-checkpoint inhibitors has revolutionized multimodal treatment. In the present article, we review current treatment options and future trends in stage IIIA-N2 NSCLC.
PMID: 34104821
Rights: info:eu-repo/semantics/openAccess
Appears in Collections:Hospitales > H. U. de Fuenlabrada > Artículos

Files in This Item:
File Description SizeFormat 
JCTRES.pdf583,7 kBAdobe PDFThumbnail

This item is licensed under a Creative Commons License Creative Commons